kw 2189 has been researched along with duocarmycin b2 in 1 studies
Studies (kw 2189) | Trials (kw 2189) | Recent Studies (post-2010) (kw 2189) | Studies (duocarmycin b2) | Trials (duocarmycin b2) | Recent Studies (post-2010) (duocarmycin b2) |
---|---|---|---|---|---|
10 | 4 | 0 | 13 | 0 | 2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asada, M; Asai, A; Gomi, K; Hirata, T; Kobayashi, E; Nagamura, S; Okabe, M; Okamoto, A; Saito, H | 1 |
1 other study(ies) available for kw 2189 and duocarmycin b2
Article | Year |
---|---|
Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors.
Topics: Animals; Antibiotics, Antineoplastic; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Duocarmycins; HeLa Cells; Humans; Indoles; Lethal Dose 50; Male; Mice; Mice, Nude; Pyrrolidinones; Sarcoma 180; Tumor Cells, Cultured | 1994 |